

**BioSig Technologies, Inc. (NASDAQ: BSGM)** is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. With the global EP market projected to reach \$10.1B in 2024 with a 11.3% growth rate, BioSig has commenced a targeted commercial release of its PURE EP™ System, generating its first commercial sale in December 2020. The Company's first product is a computerized system designed to reveal the full range of cardiac signals and to provide physicians with signal clarity during procedures performed to address cardiac arrhythmias. The PURE EP™ System received FDA 510(k) clearance in August 2018. Physicians using BioSig's PURE EP™ System have successfully completed over 1,750 patient cases to date. Systems are currently installed at multiple locations, including Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Mayo Clinic's Florida, Minnesota and Arizona campuses, Massachusetts General Hospital, the University of Pennsylvania, Deborah Heart and Lung Center, and Houston Methodist.

Data Source: 2019 DRG MedTech 360 Report

### PURE EP™ System



### Key Growth Drivers

- Advanced Technology** – The non-invasive **PURE EP System** is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology EP procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. The PURE EP System aims to minimize noise and artifacts, and acquire high-fidelity cardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly **improving accuracy and efficiency of the EP studies and ablation procedures.**
- Market Opportunity** – 2019 DRG Medtech 360 Report states the **global EP device** market is expected to exceed more than **US \$10.1 billion by 2024** and is growing at a compound annual growth rate (CAGR) of 11.3%. The Company also operates within the rapidly emerging field of **bioelectronic medicine**, estimated at **\$25.11 billion in 2020 with projected annual growth of 10.27%.**
- KOL Support** – PURE EP has been used and valued by many of the industry's leading electrophysiology physicians, including Dr. Andrea Natale of Texas Cardiac Arrhythmia Institute, and Dr. G. Joseph Gallinghouse. The Company achieved proof of concept validation through UCLA, and has performed numerous pre-clinical studies at Mayo Clinic, MN under the leadership of **Samuel J. Asirvatham, M.D.**, Mayo Clinic's Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory.

### Market Snapshot NASDAQ: BSGM

<b>Price</b> (12/19/21)	<b>\$2.65</b>
<b>Average Volume</b> (30 day)	<b>249,220</b>
<b>52-Wk. Range</b>	<b>\$2.26 - \$6.14</b>
<b>Float</b>	<b>27.5M</b>
<b>Shares Outstanding</b>	<b>35.3M</b>
<b>Market Cap</b>	<b>\$93.5M</b>

### Recent Highlights

- Announced PURE EP™ **installation agreement** with HCA Healthcare-operated Westside Regional Medical Center in Plantation, FL
- Appointed Gray Fleming as **Chief Commercial Officer**
- Initiated **Artificial Intelligence Development Program** with Technion Israel Institute of Technology
- Increased expected procedures** to 1,700 - 1,800 cases
- Clinical data acquired by PURE EP™ **published in the Journal of Cardiovascular Electrophysiology**
- Selected Plexus Corp.** as its manufacturing partner
- Announced **medical device industry leader** to its board of directors
- Entered into a **new installation agreement** with St. Elizabeth's Medical Center
- Unblinding of clinical data from PURE EP™ 2.0 Study showed **signal superiority to standard of care**
- Entered into a **new installation agreement** for evaluation with Medical City North Hills in North Richland Hills, Texas
- Completed enrollment** in the PURE EP™ 2.0 clinical study

### BioSig Technologies, Inc.

55 Greens Farms Road  
Westport, CT 06880  
[www.biosig.com](http://www.biosig.com)  
[info@biosigtech.com](mailto:info@biosigtech.com)

Contact:  
**Kenneth L. Londoner, CEO**  
Phone: (203) 409-5444 x119  
klondoner@biosigtech.com

**Investor Relations**  
Andrew Ballou  
Phone: (203) 409-5444, x133  
aballou@biosigtech.com

## PURE EP™ System

Proprietary Hardware and Software with Advanced Signal Processing Capabilities:

- To **Improve Signal Clarity** Through Reduction of ‘Noise’ and Artifacts
- To **Minimize Need for Repeat Procedures**
- To Preserve **Important Clinical Information**
- To **Shorten Procedure Times**
- To **Increase Confidence** in Performing **Complex Ablations**
- **Customizable** user control **interface** for a **better understanding of ECG and intracardiac signals**

## Projected Global EP Market—11.3% Growth reaching \$10.1B by 2024

- **Global Ablation Procedure Growth: 8.4%** growth rate, from 973,220 in 2017 to **1.45 projected million in 2022.**
- **Complex Ablation Procedures:** 440,629 in 2017 to 830,390 in 2022; **13.5% projected growth rate**
- Estimated 3,425 EP rooms in US; 3,915 EP rooms OUS

### Collaborating with Leading EPs from:



## Management and Past Experience

### Kenneth L. Londoner, MBA, Founder, Chairman, Chief Executive Officer, Director

Endicott Management Partners; J & W Seligman & Co; Director: Alliqua

### Steve Chaussy, CPA, Chief Financial Officer

Liberski Inc; Anna & Co; Penske Truck Leasing, Ford, Hogg & Cobbe

### Natasha Drapeau, Executive Vice President

IG Group Plc, London, UK; Augeous Consulting, Geneva, Switzerland

### Gray Fleming, Chief Commercial Officer

St. Jude Medical; Abbott Laboratories

### Andrew Ballou, VP, Investor Relations

Janney Montgomery Scott LLC., RBC Capital Markets

### Olivier Chaudoir, Sr. Director of Marketing

Biosense Webster, DePuy Synthes

### Ewald Riechert, Director of Regulatory Affairs

Acclarent, Allergan, Oriol STAT A MATRIX

## Proven Team

BioSig is operated by a **proven management team** and a **premier Board of Directors** with high levels of inside equity ownership.

BioSig brought together **leading physicians, executives and engineering experts from leading medical centers of excellence, healthcare programs, Fortune 500 Companies and elite educational institutions for its Advisory Board** including Mayo Clinic, Mount Sinai Medical Center, UCLA, Johnson & Johnson, Nasdaq and Prudential Securities.

**Kenneth L. Londoner, Chairman & CEO**, has a wealth of knowledge and experience that spans many decades and includes founding, running, and serving as Director to a number of life science companies. Mr. Londoner began his career with J. & W. Seligman & Co., Inc., a leading institutional money management firm where he rose from research analyst to managing \$3.5 billion in mutual funds, pension funds, and international assets.

**Steve Chaussy, CFO** has acted as a consultant for small publicly traded entities with a special emphasis towards SEC reporting and compliance; and served as CFO for a large private distribution and wholesaling company, where he gained international experience.

## Investment Highlights

- \$17.4 Million cash and no debt\*
- Achieved first revenues
- Conducted **First Clinical Trial** with PURE EP™ System
- Significant Insider Ownership
- **10-year Strategic Collaboration with Mayo Clinic**
- **IP Strategy** Led by Sherpa Technology Group and Sterne Kessler Goldstein & Fox.—37 allowed/issued design and utility patents
- **FDA clearance** achieved
- Proven Management Team and Board of Directors
- **Global and Growing Addressable Market**
- Operates Within Rapidly Emerging Field of **Bioelectronic Medicine**
- **High-Growth Sector Earns Innovation Premium, Aggressive M&A**

## Current Cardiac Arrhythmia Epidemic (1 in 18 or 14.4M Americans)

Two of the most **prevalent , complex and potentially deadly** types of arrhythmias today are **Atrial Fibrillation (AF)** and **Ventricular Tachycardia (VT)**. Ventricular arrhythmias account for approximately **300,000 sudden deaths per year** in the United States alone. Catheter ablation is fast becoming a first line therapy, driving demand for improved technologies. AF is the most common arrhythmia affecting **33.5 million people worldwide**, with as many as 6.1 million people in the U.S. now and expected 8-12 million by 2050. AF increases the risk of stroke 4x to 5x and contributes to ~750,000 hospitalizations per year. The direct cost of AF is approximately \$6B annually; adding other indirect costs brings **AF total cost to \$26B.**

## Directors

**Donald E. Foley, Director** - Former CEO & Chair: Wilmington Trust; Sr VP, Treas & Dir: ITT Corp; Asst Treas: International Paper Co.

**David Weild IV, MBA, Director** - Current Chairman & CEO; Weild & Co.; Former Vice Chairman: NASDAQ; Former Head of Corporate Finance & Equity Markets: Prudential Securities

**Patrick J. Gallagher, MBA, Director** - Mg Dir: Laidlaw & Co.; Kinex Pharmaceuticals; Director: Cingulate Therapeutics, BDR Research Group, GC Capital Partners, Kidder Peabody

**Samuel E. Navarro, Director** - Managing Partner: Gravitas Healthcare, LLC; Former Managing Director and Global Head of Medical Technology Investment Banking: Cowen & Company

**Anthony Zook, Director** - Former Vice President & Executive Officer at AstraZeneca Plc

**James J. Barry, Director** - Principal Owner; Convergent Biomedical Group LLC; former President and CEO; InspireMD, Inc.; former SVP of Corporate Technology at Boston Scientific

## Analyst Coverage: Laidlaw & Co (UK) Ltd., Trickle Research, & Intro-act

Disclaimer: This Corporate Summary Sheet includes forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, regulatory approvals, competition and marketplace demand. More information, and BioSig risk factors, are set forth in its filings with the SEC. BioSig assumes no obligation to publicly update or revise its forward-looking statements. Data Sources: 2018 MD&D report, Worldwide Epidemiology of Atrial Fibrillation in the journal Circulation, 2013; CDC Fact Sheet on Atrial Fibrillation; American Heart Association; Ventricular Tachycardia in Medscape, December 2017; “Healthcare Costs Drop Sharply after Successful Ablation,” Marlene Busko, Medscape, May 4, 2016 , and Bioelectronic Medicine 2019-2029. IDTechEx Research. \*As reported in the 09/30/21 form 10Q filed on November 15th, 2021.